Bio-Layer Interferometry (BLI) Molecular Interaction Lab

Model thin-film optical interference, fluidics-free dip-and-read sensorgrams, 1:1 binding kinetics, crude IgG titer quantitation, and testing facility cash flows.

Fluidics-Free Dip & Read 10-Yr DCF Model
Affinity (KD)
0.60 nM
koff / kon
Complex Half-Life
77.0 min
ln(2) / koff
Equilibrium Shift (Req)
1.78 nm
Optical Thickness Δλ
Initial Slope (Titer)
22.5 pm/s
Quantitation Rate
Facility 10-Yr NPV
$1,180,400
10% WACC
Internal IRR
94.8%
Payback: 1.0 yrs

Interferometer Parameters

Live Solver
Analyte Concentration (C): 50 nM
Association Rate (kon): 2.50 × 10⁵ M⁻¹s⁻¹
Dissociation Rate (koff): 1.50 × 10⁻⁴ s⁻¹
Max Shift Capacity (Rmax): 1.80 nm
Association Time: 300 s
Dissociation Time: 400 s

Testing Facility DCF Economics

Automated 8-Ch BLI CapEx: $165,000
Annual Plate Assays: 2,000
Testing Fee / Sample: $110

Optical Interference Spectrum (Reflected Wavelength Shift)

Thin-film periodic reflectance fringes shifting towards longer wavelengths upon binding
Biosensor Tip Optics
Interference shift formula: Δλ = 2 · Δ(n · d) / m Spectral red shift directly proportional to bound surface mass density

Real-Time Dip-and-Read Sensorgram (Δλ vs Time)

Baseline, association (kon), and dissociation (koff) dip-and-read phases
Langmuir 1:1 Kinetics
Association curvature resolves kobs = kon[C] + koff Dissociation slope directly determines off-rate: R(t) = R0e-kofft

5-Year BLI Testing Lab Cash Flow Schedule

Period Revenue OpEx EBITDA Free Cash Flow Discounted FCF

1. Bio-Layer Thin-Film Optical Interferometry

Bio-Layer Interferometry (BLI) operates by directing white light through a glass biosensor coated with a biocompatible molecular matrix at the tip:

  • Two Reflection Surfaces: Light reflects from an internal reference optical layer and from the biomolecular layer at the external sensor tip.
  • Constructive & Destructive Interference: Reflections combine to create a characteristic interference spectrum across visible wavelengths.
  • Real-Time Wavelength Shift: When analyte binds to immobilized ligand, the optical thickness increases ($\Delta(n \cdot d)$), shifting the spectral interference pattern ($\Delta\lambda$ in nm) in real time.

2. Fluidics-Free "Dip-and-Read" Architecture

The defining operational differentiator of BLI compared to traditional microfluidic SPR systems is its fluidics-free dip-and-read format:

  • Zero Microfluidic Clogging: Biosensors move directly from well to well in standard 96-well or 384-well microplates under orbital shaking (1000 rpm), completely eliminating fluidic microchannel blockages.
  • Crude Sample Compatibility: Direct kinetic analysis and quantitation in unpurified bioreactor supernatants, bacterial periplasmic lysates, and serum without filtration.
  • Sensor Regeneration & Reusability: Biosensors can be rapidly stripped and regenerated through multiple cycles, reducing consumable expenditure.

3. High-Throughput Titer & Epitope Binning

BLI accelerates biotherapeutic development across screening and early discovery workflows:

  • Initial-Rate Titer Quantitation: Under mass-transport-limited binding, initial slopes ($dR/dt$) directly quantify antibody concentration ($1–2000\ \mu\text{g/mL}$) in under 2 minutes per sample.
  • In-Tandem Epitope Binning: Cross-competition assays determine whether antibody candidate pairs share identical, overlapping, or distinct non-competing epitopes on target antigens.
  • Multiplexed Parallelism: Simultaneous reading across 8 or 16 channels processes entire 96-well plates in under 15 minutes.

4. Commercial Testing Facility Economics & DCF

Biopharma analytical core laboratories and contract research organizations achieve rapid capital payback with automated BLI systems:

  • Capital Investment: Modern 8-channel automated BLI systems (e.g., Sartorius Octet R8, Gator Bio) require approximately \$150,000 to \$180,000 CapEx.
  • Operational Cost Efficiency: Low maintenance with no fluidic pumps, seals, or degassers; operating expenses consist primarily of disposable biosensors and 96-well plates.
  • Exceptional Cash Flow: Testing fees of \$80 to \$140 per sample across 2,000 annual assays yield over \$220,000 in gross revenue, achieving full capital payback in approximately 1.0 year and internal rates of return exceeding 90%.

Frequently Asked Questions: Bio-Layer Interferometry

Bio-Layer Interferometry (BLI) is an optical analytical technique that measures molecular binding events in real time at the tip of disposable biosensors. White light directed down the biosensor reflects from two surfaces: an internal reference layer and a biocompatible surface chemistry layer where molecules bind. Binding increases optical thickness (n * d), creating a phase shift in reflected light waves that produces a measurable shift in the interference pattern wavelength (Δλ in nanometers).

Unlike Surface Plasmon Resonance (SPR), which relies on microfluidic flow cells and gold prism couplers that are vulnerable to clogging and refractive index bulk shifts, BLI utilizes a fluidics-free "dip-and-read" format in standard 96-well or 384-well microplates. This enables direct analysis of unpurified samples such as crude cell culture supernatants, bacterial lysates, and serum without pre-clearing or fluidic clogging risks.

In quantitation mode, Protein A or Protein G biosensors are dipped into crude cell broth. Under mass-transport-limited conditions, the initial rate of binding (initial slope dR/dt in nm/s) is directly proportional to antibody concentration. By calibrating against a standard curve of known concentrations, BLI accurately determines IgG titers from 1 to 2000 µg/mL in as little as 2 minutes per sample.

In-tandem epitope binning assesses whether two monoclonal antibodies bind to overlapping or distinct epitopes on a target antigen. An antigen-coated biosensor is first saturated with Antibody 1, followed immediately by exposure to Antibody 2. If Antibody 2 produces a secondary wavelength shift, both antibodies bind simultaneously to non-competing distinct epitopes; if no additional shift occurs, they compete for the same or overlapping steric epitope.

Automated 8-channel or 16-channel BLI platforms (such as Sartorius Octet R8 or Gator Bio) require capital investments around $150,000 to $200,000. Operating costs include disposable biosensor trays and assay plates. With testing fees of $80 to $150 per sample and annual throughput exceeding 2,000 runs across titer screening and kinetic characterization, automated BLI platforms generate strong cash flows, achieving capital payback in approximately 1.0 to 1.2 years.

Knowledge Check: BLI Principles & Optical Metrology

Related Biophysical & Molecular Interaction Tools

SPR Molecular Binding Lab
ITC Binding Thermodynamics Lab
Nano-DSC Protein Stability Lab
Circular Dichroism CD Lab
DLS & Zeta Potential Lab
Laser Diffraction PSD Lab
NTA Nanoparticle Tracking Lab